Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from GlaxoSmithKline.

Exploring Current and Emerging Data Sets to Move Treatment of Ovarian Cancer Forward: A Focus on PARP Inhibition, Immunotherapy, and Beyond!

Release Date: July 21, 2020
Expiration Date: July 21, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in ovarian cancer for an in-depth discussion covering key aspects of the latest advancements in therapy, including PARP inhibition and immunotherapy. The activity highlights the current and emerging therapeutic strategies for the treatment of ovarian cancer, current challenges in the clinical care of patients with ovarian cancer, and forecasts changes in the dynamic treatment landscape of ovarian cancer based on the latest data from clinical trials.

This educational activity is an archive of the live virtual symposium held on July 1, 2020.

Acknowledgement of Support

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Integrate molecular testing and its application in selection of therapy for patients with newly diagnosed and recurrent ovarian cancer
  • Discuss the rationale for maintenance therapy in the management of ovarian cancer
  • Describe the efficacy and safety of PARP inhibitors in the setting of frontline and recurrent ovarian cancer
  • Identify strategies for the prevention, recognition, and management of AEs associated with new and emerging treatments for ovarian cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Director and Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Merck, Novartis; Other: Travel: AstraZeneca

Susana M. Campos, MD, MPH
Susana M. Campos, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant Research Support: Tesaro, GlaxoSmithKline; Consultant: Tesaro, Eisai

Bradley Monk, MD, FACS, FACOG
Bradley Monk, MD, FACS, FACOG
Professor, Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Phoenix Creighton University School of Medicine at St. Joseph's Hospital Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Agenus, Akesio Amgen, Aravive, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical, ChemoCare, ChemoID, Clovis Oncology, Dicephera Pharmaceuticals, Eisai, Geistlich, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Immunomedics, Incyte, Iovance Biotherapeutics, Laekna Healthcare, Merck, Mersana Therapeutics, Myriad, NuCana, OncoMed Pharmaceuticals, OncoQuest, OncoSec, Perthera, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, Senti Biosciences, Takeda Pharmaceutical Company Limited, Tarveda Therapeutics, Tesaro/GlaxoSmithKline, Vavotar Life Sciences, VBL Therapeutics, Vigeo; Speakers Bureau: AstraZeneca, Clovis Oncology, Eisai, Merck, Roche/Genentech, Tesaro/GlaxoSmithKline

Kathleen N. Moore, MD
Kathleen N. Moore, MD
Director, Oklahoma TSET Phase I Program, Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology, Director Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, OK

Disclosures: Consultant: AbbVie, Aravive, AstraZeneca, Clovis, Eisai, Tesaro/GlaxoSmithKline, Genentech/Roche, ImmunoGen, Merck, Mersana Therapeutics, Myriad, Perthera, Tarveda Therapeutics, VBL Therapeutics.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By